Flecainide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
'''''For patient information about Flecainide, click [[Flecainide (patient information)|here]].''''' | '''''For patient information about Flecainide, click [[Flecainide (patient information)|here]].''''' | ||
{{SB}} FLECAINIDE ACETATE | {{SB}} FLECAINIDE ACETATE<sup>®</sup> | ||
==Overview== | ==Overview== | ||
==Category== | ==Category== | ||
[[Antiarrhythmic agents]];[[Piperidines]];[[Benzamides]];[[Phenol ethers]];[[Organofluorides]];[[Sodium channel blockers]];[[Cardiovascular Drugs]] | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
==== | ====FLECAINIDE ACETATE tablet ==== | ||
''' [[Flecainide indications and usage|Indications and Usage]]''' | ''' [[Flecainide indications and usage|Indications and Usage]]''' | ||
| Line 33: | Line 35: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Flecainide works by blocking the Nav1.5 [[sodium channel]] in the heart, causing prolongation of the [[cardiac action potential]].<ref name = Ramos>{{cite journal | author = Ramos E, O'leary M | title = State-dependent trapping of flecainide in the cardiac sodium channel | journal = J Physiol | volume = 560 | issue = Pt 1 | pages = 37–49 | year = 2004 | pmid = 15272045 | doi = 10.1113/jphysiol.2004.065003 | pmc = 1665201}}</ref> This thereby slows conduction of the electrical impulse within the heart. The greatest effect is on the [[electrical conduction system of the heart|His-Purkinje system]] and ventricular [[myocardium]]. The effect of flecainide on the ventricular myocardium causes decreased contractility of the muscle, which leads to a decrease in the ejection fraction. | |||
The effect of flecainide on the [[sodium channels]] of the heart increases as the heart rate increases.<ref name = Wang>{{cite journal | author = Wang Z, Fermini B, Nattel S | title = Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue | journal = J Pharmacol Exp Ther | volume = 267 | issue = 2 | pages = 575–81 | year = 1993 | pmid = 8246130}}</ref> This is known as use-dependence. This means that flecainide is potentially more useful to break a [[tachyarrhythmia]] (because it has increased effect during the fast heart rate) than to prevent a [[bradyarrhythmia]] from occurring (because of its lowered effectiveness during slower heart rates). | |||
==Interaction with Alcohl== | |||
Concomitant overdose of other drugs and/or alcohol in many instances undoubtedly contributed to the fatal outcome. | |||
==References== | ==References== | ||
{{Reflist}} | |||
{{ | {{Antiarrhythmic agents}} | ||
[[Category:Antiarrhythmic agents]] | |||
[[Category:Piperidines]] | |||
[[Category:Benzamides]] | |||
[[Category:Phenol ethers]] | |||
[[Category:Organofluorides]] | |||
[[Category:Sodium channel blockers]] | |||
[[Category:Cardiovascular Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 14:09, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Flecainide, click here.
Synonyms / Brand Names: FLECAINIDE ACETATE®
Overview
Category
Antiarrhythmic agents;Piperidines;Benzamides;Phenol ethers;Organofluorides;Sodium channel blockers;Cardiovascular Drugs
FDA Package Insert
FLECAINIDE ACETATE tablet
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Flecainide works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.[1] This thereby slows conduction of the electrical impulse within the heart. The greatest effect is on the His-Purkinje system and ventricular myocardium. The effect of flecainide on the ventricular myocardium causes decreased contractility of the muscle, which leads to a decrease in the ejection fraction.
The effect of flecainide on the sodium channels of the heart increases as the heart rate increases.[2] This is known as use-dependence. This means that flecainide is potentially more useful to break a tachyarrhythmia (because it has increased effect during the fast heart rate) than to prevent a bradyarrhythmia from occurring (because of its lowered effectiveness during slower heart rates).
Interaction with Alcohl
Concomitant overdose of other drugs and/or alcohol in many instances undoubtedly contributed to the fatal outcome.
References
- ↑ Ramos E, O'leary M (2004). "State-dependent trapping of flecainide in the cardiac sodium channel". J Physiol. 560 (Pt 1): 37–49. doi:10.1113/jphysiol.2004.065003. PMC 1665201. PMID 15272045.
- ↑ Wang Z, Fermini B, Nattel S (1993). "Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue". J Pharmacol Exp Ther. 267 (2): 575–81. PMID 8246130.